• RXC004 Phase 1 monotherapy data to be presented at ESMO Congress 2021

    Read more
  • Interim results for the six months ended 31 March

    Read more
  • Appointment of Peter Collum, as Chief Financial Officer

    Read more
  • Redx Pharma begin phase I trial to discover potential of its cancer drug as a combination therapy (proactiveinvestors.co.uk)

    Read more
  • Dosing of first patients with RXC004 and Anti-PD1

    Read more
  • Redx Pharma to present at the American Association for Cancer Research Annual Meeting

    Read more
  • Appointment of Joint Broker

    Read more
  • Lisa Anson discusses life science funding and investment with Pharmaphorum (Podcast)

    Read more
  • Result of AGM and Directorate change

    Read more
  • New Grant of Options

    Read more